{"id":"https://openalex.org/W2159254757","doi":"https://doi.org/10.1111/j.1365-2702.2009.03167.x","title":"Safety profiles of second\u2010line tyrosine kinase inhibitors in patients with chronic myeloid leukaemia","display_name":"Safety profiles of second\u2010line tyrosine kinase inhibitors in patients with chronic myeloid leukaemia","publication_year":2010,"publication_date":"2010-03-16","ids":{"openalex":"https://openalex.org/W2159254757","doi":"https://doi.org/10.1111/j.1365-2702.2009.03167.x","mag":"2159254757","pmid":"https://pubmed.ncbi.nlm.nih.gov/20345830"},"language":"en","primary_location":{"id":"doi:10.1111/j.1365-2702.2009.03167.x","doi":"https://doi.org/10.1111/j.1365-2702.2009.03167.x","is_oa":false,"landing_page_url":"https://doi.org/10.1111/j.1365-2702.2009.03167.x","pdf_url":null,"source":{"id":"https://openalex.org/S180106345","display_name":"Journal of Clinical Nursing","issn_l":"0962-1067","issn":["0962-1067","1365-2702"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Nursing","raw_type":"journal-article"},"volume":null,"type":"review","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5076396878","display_name":"Sara Tinsley","orcid":"https://orcid.org/0000-0003-3012-7398","observed_orcids":["https://orcid.org/0000-0003-3012-7398"]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Sara M Tinsley","raw_affiliation_strings":["Moffitt Cancer Center, Tampa, FL 33612, USA. sara.tinsley@moffitt.org","Author:Sara M Tinsley, ARNP, MS, AOCN, Nurse Practitioner, Moffitt Cancer Center, Tampa, FL, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Moffitt Cancer Center, Tampa, FL 33612, USA. sara.tinsley@moffitt.org","institution_ids":["https://openalex.org/I3019308854"]},{"raw_affiliation_string":"Author:Sara M Tinsley, ARNP, MS, AOCN, Nurse Practitioner, Moffitt Cancer Center, Tampa, FL, USA","institution_ids":["https://openalex.org/I3019308854"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5076396878"],"corresponding_institution_ids":["https://openalex.org/I3019308854"],"apc_list":{"value":5450,"currency":"USD","value_usd":5450},"apc_paid":null,"fwci":0.2534,"has_fulltext":false,"cited_by_count":8,"citation_normalized_percentile":{"value":0.2459893,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":96},"biblio":{"volume":"19","issue":"9-10","first_page":"1207","last_page":"1218"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11215","display_name":"Chronic Myeloid Leukemia Treatments","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11215","display_name":"Chronic Myeloid Leukemia Treatments","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.00039999998989515007,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/chronic-myeloid-leukemia","display_name":"chronic myeloid leukemia","score":0.9950000047683716},{"id":"https://openalex.org/keywords/tyrosine-kinase-inhibitors","display_name":"tyrosine kinase inhibitors","score":0.9430000185966492},{"id":"https://openalex.org/keywords/second-line-treatment","display_name":"second-line therapy","score":0.7919999957084656},{"id":"https://openalex.org/keywords/dasatinib","display_name":"dasatinib","score":0.9940000176429749},{"id":"https://openalex.org/keywords/nilotinib","display_name":"nilotinib","score":1.0},{"id":"https://openalex.org/keywords/high-dose-imatinib","display_name":"high-dose imatinib","score":0.9330000281333923},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.7350000143051147},{"id":"https://openalex.org/keywords/fluid-retention","display_name":"fluid retention","score":0.7490000128746033},{"id":"https://openalex.org/keywords/cardiotoxicity","display_name":"cardiotoxicity","score":0.9980000257492065},{"id":"https://openalex.org/keywords/cytopenia","display_name":"cytopenia","score":0.8119999766349792},{"id":"https://openalex.org/keywords/nursing-management","display_name":"nursing management","score":0.6489999890327454}],"concepts":[{"id":"https://openalex.org/C2777413986","wikidata":"https://www.wikidata.org/wiki/Q412327","display_name":"Nilotinib","level":4,"score":0.9776591062545776},{"id":"https://openalex.org/C2779536868","wikidata":"https://www.wikidata.org/wiki/Q419940","display_name":"Dasatinib","level":4,"score":0.9542169570922852},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8997746706008911},{"id":"https://openalex.org/C2777583451","wikidata":"https://www.wikidata.org/wiki/Q177094","display_name":"Imatinib","level":3,"score":0.8325791358947754},{"id":"https://openalex.org/C42362537","wikidata":"https://www.wikidata.org/wiki/Q87099740","display_name":"Tyrosine kinase","level":3,"score":0.6080552935600281},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.565265953540802},{"id":"https://openalex.org/C2778820342","wikidata":"https://www.wikidata.org/wiki/Q906415","display_name":"Tyrosine-kinase inhibitor","level":3,"score":0.5639469623565674},{"id":"https://openalex.org/C2778233292","wikidata":"https://www.wikidata.org/wiki/Q2118956","display_name":"Cardiotoxicity","level":3,"score":0.5236917734146118},{"id":"https://openalex.org/C2778729363","wikidata":"https://www.wikidata.org/wiki/Q11688946","display_name":"Myeloid leukemia","level":2,"score":0.5096769332885742},{"id":"https://openalex.org/C3019892230","wikidata":"https://www.wikidata.org/wiki/Q177094","display_name":"Imatinib mesylate","level":4,"score":0.44525179266929626},{"id":"https://openalex.org/C2778208673","wikidata":"https://www.wikidata.org/wiki/Q894611","display_name":"Bosutinib","level":5,"score":0.4274975657463074},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.40228158235549927},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3974418044090271},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.3628852367401123},{"id":"https://openalex.org/C177713679","wikidata":"https://www.wikidata.org/wiki/Q679690","display_name":"Intensive care medicine","level":1,"score":0.3209291696548462},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.10623759031295776},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.09962481260299683},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011505","descriptor_name":"Protein-Tyrosine Kinases","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D015464","descriptor_name":"Leukemia, Myelogenous, Chronic, BCR-ABL Positive","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1111/j.1365-2702.2009.03167.x","doi":"https://doi.org/10.1111/j.1365-2702.2009.03167.x","is_oa":false,"landing_page_url":"https://doi.org/10.1111/j.1365-2702.2009.03167.x","pdf_url":null,"source":{"id":"https://openalex.org/S180106345","display_name":"Journal of Clinical Nursing","issn_l":"0962-1067","issn":["0962-1067","1365-2702"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Nursing","raw_type":"journal-article"},{"id":"pmid:20345830","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/20345830","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of clinical nursing","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"sustainable_development_goals_aurora":[{"score":0.800000011920929,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320307115","display_name":"Bristol-Myers Squibb","ror":"https://ror.org/00gtmwv55"}],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":35,"referenced_works":["https://openalex.org/W1510546584","https://openalex.org/W1970962784","https://openalex.org/W1974565168","https://openalex.org/W1990020715","https://openalex.org/W1990406235","https://openalex.org/W1998593414","https://openalex.org/W2003973314","https://openalex.org/W2004492241","https://openalex.org/W2006917576","https://openalex.org/W2020092689","https://openalex.org/W2023117511","https://openalex.org/W2028728760","https://openalex.org/W2028959752","https://openalex.org/W2040396943","https://openalex.org/W2057718276","https://openalex.org/W2070683532","https://openalex.org/W2079446921","https://openalex.org/W2080125373","https://openalex.org/W2097946794","https://openalex.org/W2107268345","https://openalex.org/W2116153687","https://openalex.org/W2119010176","https://openalex.org/W2124196948","https://openalex.org/W2126742110","https://openalex.org/W2274981692","https://openalex.org/W2281742031","https://openalex.org/W2312804644","https://openalex.org/W2522656204","https://openalex.org/W2558733660","https://openalex.org/W2565606062","https://openalex.org/W2576284040","https://openalex.org/W2587803351","https://openalex.org/W2612051898","https://openalex.org/W2979395636","https://openalex.org/W3151598270"],"related_works":["https://openalex.org/W2326848008","https://openalex.org/W2015061486","https://openalex.org/W2561794415","https://openalex.org/W2084325524","https://openalex.org/W2319875092","https://openalex.org/W2246006077","https://openalex.org/W3188905815","https://openalex.org/W2153151008","https://openalex.org/W1800349813","https://openalex.org/W2883886173"],"abstract_inverted_index":{"AIMS":[0],"AND":[1],"OBJECTIVES:":[2],"To":[3],"review":[4],"the":[5,39,48,56,63,118,155],"use":[6],"of":[7,33,41,65,93,142,207,218],"second-line":[8,77],"tyrosine":[9,42],"kinase":[10,43],"inhibitors":[11,44],"in":[12],"patients":[13],"with":[14,38,115,145],"chronic":[15],"myeloid":[16],"leukaemia":[17],"(CML)":[18],"and":[19,69,96,117,123,125,135,174,184,201,212,223],"provide":[20],"recommendations":[21],"for":[22,62,80,100,157,198],"managing":[23],"adverse":[24],"events":[25],"(AEs)":[26],"to":[27,171,182,227],"maximise":[28],"patient":[29],"benefit.":[30],"BACKGROUND:":[31],"Treatment":[32],"CML":[34,81],"has":[35,112,138,154],"been":[36],"revolutionised":[37],"advent":[40],"(TKIs)":[45],"that":[46],"target":[47],"breakpoint":[49],"cluster":[50],"region-Abelson":[51],"(BCR-ABL)":[52],"kinase.":[53],"Imatinib":[54],"is":[55,180,225],"only":[57],"first-line":[58,146],"TKI":[59,173],"currently":[60],"available":[61],"treatment":[64,78,235],"CML;":[66],"however,":[67],"intolerance":[68],"resistance":[70],"remain":[71],"significant":[72],"clinical":[73],"challenges.":[74],"The":[75,215],"approved":[76],"options":[79],"are":[82,166],"dasatinib,":[83],"nilotinib":[84],"or":[85],"escalated-dose":[86],"imatinib.":[87,147,163],"DESIGN:":[88],"Review":[89],"article.":[90],"METHODS:":[91],"Searches":[92],"PubMed,":[94],"ASCO":[95],"ASH":[97],"electronic":[98],"databases":[99],"relevant":[101],"search":[102],"terms":[103],"were":[104],"performed":[105],"between":[106],"July":[107],"2008-January":[108],"2009.":[109],"FINDINGS:":[110],"Dasatinib":[111],"no":[113],"cross-intolerance":[114,144],"imatinib,":[116],"most":[119],"frequent":[120],"AEs":[121,160,210],"(cytopenias":[122],"pleural":[124],"pericardial":[126],"effusions)":[127],"can":[128],"generally":[129],"be":[130,150,205],"managed":[131],"by":[132,177],"dose":[133],"interruption":[134],"reduction.":[136],"Nilotinib":[137],"a":[139],"high":[140],"degree":[141],"haematologic":[143],"As":[148],"might":[149],"expected,":[151],"high-dose":[152],"imatinib":[153],"potential":[156,197],"more":[158],"severe":[159],"than":[161],"standard-dose":[162],"CONCLUSIONS:":[164],"There":[165],"known":[167],"safety":[168,216],"issues":[169],"inherent":[170],"each":[172],"close":[175],"monitoring":[176],"nursing":[178],"staff":[179],"necessary":[181],"identify":[183],"effectively":[185],"manage":[186],"AEs.":[187],"RELEVANCE":[188],"TO":[189],"CLINICAL":[190],"PRACTICE:":[191],"All":[192],"three":[193],"TKIs":[194,220],"have":[195],"demonstrated":[196],"fluid":[199],"retention":[200],"cardiotoxicity.":[202],"Nurses":[203],"should":[204],"aware":[206],"how":[208],"these":[209,219],"manifest":[211],"intervene":[213],"appropriately.":[214],"profiles":[217],"clearly":[221],"differs":[222],"it":[224],"important":[226],"consider":[228],"factors":[229],"such":[230],"as":[231],"comorbidities":[232],"when":[233],"making":[234],"decisions.":[236]},"counts_by_year":[{"year":2022,"cited_by_count":1},{"year":2016,"cited_by_count":1},{"year":2014,"cited_by_count":1},{"year":2013,"cited_by_count":2},{"year":2012,"cited_by_count":2}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}